Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
The purpose of this study is to determine that systemic chemotherapy is superior to transcatheter arterial chemoembolization in prolonging progression-free survival（PFS） in patients with Advanced Hepatocellular Carcinoma.
Hepatocellular Carcinoma
DRUG: Pirarubicin|DRUG: Oxaliplatin|DRUG: Lipiodol|DEVICE: Gelfoam
Progression-Free-Survival, 3 months
Objective response rate, 3 months|Overall survival, 6 months and 12 months|Time-to-Progression, 3 months|Time-to-Progression within liver, 3 months|Time-to-Progression outside the liver, 3 months
The purpose of this study is to determine that systemic chemotherapy is superior to transcatheter arterial chemoembolization in prolonging progression-free survival（PFS） in patients with Advanced Hepatocellular Carcinoma.